flecainide has been researched along with Sensitivity and Specificity in 19 studies
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).
Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The mechanism of the action of flecainide in the termination of human atrial fibrillation (AF) is not fully understood." | 9.14 | Increase in organization index predicts atrial fibrillation termination with flecainide post-ablation: spectral analysis of intracardiac electrograms. ( Jeilan, M; Kundu, S; Mantravadi, R; Ng, GA; Osman, F; Stafford, PJ; Tuan, J, 2010) |
| "The efficacy and safety of the single oral loading dose of flecainide for cardioversion of recent-onset atrial fibrillation was examined by reviewing the trials on the subject identified through a comprehensive literature search." | 8.82 | Oral loading single dose flecainide for pharmacological cardioversion of recent-onset atrial fibrillation. ( Khan, IA, 2003) |
| "As a molecular model of the effect of ischemia on drug block of the transient outward potassium current, the effect of acidosis on the blocking properties of flecainide and quinidine on Kv4." | 7.72 | Extracellular acidosis modulates drug block of Kv4.3 currents by flecainide and quinidine. ( Bauskin, A; Breit, S; Bursill, J; Campbell, T; Singarayar, S; Vandenberg, J; Wu, W; Wyse, K, 2003) |
| "Flecainide testing is a valid and safe tool to identify SCN5A-related BrS patients." | 5.33 | Diagnostic value of flecainide testing in unmasking SCN5A-related Brugada syndrome. ( Bezzina, CR; Hofman, N; Meregalli, PG; Ruijter, JM; Tan, HL; Wilde, AA, 2006) |
| "The mechanism of the action of flecainide in the termination of human atrial fibrillation (AF) is not fully understood." | 5.14 | Increase in organization index predicts atrial fibrillation termination with flecainide post-ablation: spectral analysis of intracardiac electrograms. ( Jeilan, M; Kundu, S; Mantravadi, R; Ng, GA; Osman, F; Stafford, PJ; Tuan, J, 2010) |
| "The efficacy and safety of the single oral loading dose of flecainide for cardioversion of recent-onset atrial fibrillation was examined by reviewing the trials on the subject identified through a comprehensive literature search." | 4.82 | Oral loading single dose flecainide for pharmacological cardioversion of recent-onset atrial fibrillation. ( Khan, IA, 2003) |
| "As a molecular model of the effect of ischemia on drug block of the transient outward potassium current, the effect of acidosis on the blocking properties of flecainide and quinidine on Kv4." | 3.72 | Extracellular acidosis modulates drug block of Kv4.3 currents by flecainide and quinidine. ( Bauskin, A; Breit, S; Bursill, J; Campbell, T; Singarayar, S; Vandenberg, J; Wu, W; Wyse, K, 2003) |
| "The Brugada syndrome is a heterogeneous genetic disease that predisposes to life-threatening ventricular tachyarrhythmias and sudden cardiac death (SCD)." | 1.39 | Positive Brugada challenge test in V1 R-V3 R as a predictor of malignant prognosis in Brugada patients. ( Aslani, A; Emkanjoo, Z; Hashemi, A; Saber, S; Shahrzad, S; Taban, S, 2013) |
| "Flecainide testing is a valid and safe tool to identify SCN5A-related BrS patients." | 1.33 | Diagnostic value of flecainide testing in unmasking SCN5A-related Brugada syndrome. ( Bezzina, CR; Hofman, N; Meregalli, PG; Ruijter, JM; Tan, HL; Wilde, AA, 2006) |
| "The flecainide test was negative in 14 and positive in 18 subjects." | 1.32 | QT-interval prolongation in right precordial leads: an additional electrocardiographic hallmark of Brugada syndrome. ( Anaclerio, M; Forleo, C; Guida, P; Iacoviello, M; Manghisi, A; Massari, F; Mastropasqua, F; Pitzalis, MV; Rizzon, P; Sorrentino, S; Troccoli, R, 2003) |
| "Flecainide and quinidine were less potent inhibitors of IK than was propafenone with IC50s of 15 and 14 microM compared with an IC50 of 5 microM for propafenone." | 1.29 | K+ channel blocking actions of flecainide compared with those of propafenone and quinidine in adult rat ventricular myocytes. ( Castle, NA; Slawsky, MT, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (26.32) | 18.2507 |
| 2000's | 11 (57.89) | 29.6817 |
| 2010's | 3 (15.79) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hashemi, A | 1 |
| Shahrzad, S | 2 |
| Saber, S | 1 |
| Taban, S | 1 |
| Aslani, A | 1 |
| Emkanjoo, Z | 1 |
| Doki, K | 2 |
| Sekiguchi, Y | 1 |
| Kuga, K | 2 |
| Aonuma, K | 1 |
| Kohda, Y | 2 |
| Homma, M | 2 |
| Tanel, RE | 1 |
| Tuan, J | 1 |
| Osman, F | 1 |
| Jeilan, M | 1 |
| Kundu, S | 1 |
| Mantravadi, R | 1 |
| Stafford, PJ | 1 |
| Ng, GA | 1 |
| Bollmann, A | 1 |
| Binias, KH | 1 |
| Toepffer, I | 1 |
| Molling, J | 1 |
| Geller, C | 1 |
| Klein, HU | 1 |
| Khan, IA | 1 |
| Singarayar, S | 1 |
| Bursill, J | 1 |
| Wyse, K | 1 |
| Bauskin, A | 1 |
| Wu, W | 1 |
| Vandenberg, J | 1 |
| Breit, S | 1 |
| Campbell, T | 1 |
| Pitzalis, MV | 1 |
| Anaclerio, M | 1 |
| Iacoviello, M | 1 |
| Forleo, C | 1 |
| Guida, P | 1 |
| Troccoli, R | 1 |
| Massari, F | 1 |
| Mastropasqua, F | 1 |
| Sorrentino, S | 1 |
| Manghisi, A | 1 |
| Rizzon, P | 1 |
| Watanabe, S | 1 |
| Yamaguchi, I | 1 |
| Beldner, S | 1 |
| Lin, D | 1 |
| Marchlinski, FE | 1 |
| Füessl, HS | 1 |
| Meregalli, PG | 1 |
| Ruijter, JM | 1 |
| Hofman, N | 1 |
| Bezzina, CR | 1 |
| Wilde, AA | 1 |
| Tan, HL | 1 |
| Somberg, JC | 1 |
| Slawsky, MT | 1 |
| Castle, NA | 1 |
| Reeb, T | 1 |
| de Chillou, C | 1 |
| Sadoul, N | 1 |
| Lacour, JC | 1 |
| Ducrocq, X | 1 |
| Debouverie, M | 1 |
| Weber, M | 1 |
| Aliot, E | 1 |
| Antonielli, E | 1 |
| Pizzuti, A | 1 |
| Pálinkás, A | 1 |
| Tanga, M | 1 |
| Gruber, N | 1 |
| Michelassi, C | 1 |
| Varga, A | 1 |
| Bonzano, A | 1 |
| Gandolfo, N | 1 |
| Halmai, L | 1 |
| Bassignana, A | 1 |
| Imran, MB | 1 |
| Delnevo, F | 1 |
| Csanády, M | 1 |
| Picano, E | 1 |
| Lensmeyer, GL | 1 |
| Wiebe, DA | 1 |
| Doran, TC | 1 |
| Fischer, C | 1 |
| Bühl, K | 1 |
| Bhandari, AK | 1 |
| Anderson, JL | 1 |
| Gilbert, EM | 1 |
| Alpert, BL | 1 |
| Henthorn, RW | 1 |
| Waldo, AL | 1 |
| Cullen, MT | 1 |
| Hawkinson, RW | 1 |
| Pritchett, EL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Clinical Trial to Study Pharmacological Cardioversion of Paroxysmal Atrial Fibrillation by Vernakalant and Flecainide[NCT03005366] | Phase 4 | 50 participants (Actual) | Interventional | 2017-01-31 | Completed | ||
| Risk Factors That Contribute to the Maintenance of Sinus Rhythm: A Prospective Study to Create a Prediction Model for Atrial Fibrillation Patients to Maintain Sinus Rhythm.[NCT04655443] | 77 participants (Actual) | Observational | 2017-08-29 | Terminated (stopped due to due to COVID-19) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for flecainide and Sensitivity and Specificity
| Article | Year |
|---|---|
Oral loading single dose flecainide for pharmacological cardioversion of recent-onset atrial fibrillation.
Topics: Administration, Oral; Adult; Aged; Atrial Fibrillation; Biological Availability; Controlled Clinical | 2003 |
2 trials available for flecainide and Sensitivity and Specificity
| Article | Year |
|---|---|
Increase in organization index predicts atrial fibrillation termination with flecainide post-ablation: spectral analysis of intracardiac electrograms.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Electrophysiologic Techniques, Cardiac; Fe | 2010 |
Clinical value of left atrial appendage flow for prediction of long-term sinus rhythm maintenance in patients with nonvalvular atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Blood Flow Velocity; Echocardiography, Doppler, P | 2002 |
16 other studies available for flecainide and Sensitivity and Specificity
| Article | Year |
|---|---|
Positive Brugada challenge test in V1 R-V3 R as a predictor of malignant prognosis in Brugada patients.
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Brugada Syndrome; Electrocardiography; Female; Flecainide | 2013 |
Stereoselective analysis of flecainide enantiomers using reversed-phase liquid chromatography for assessing CYP2D6 activity.
Topics: Adult; Chromatography, Reverse-Phase; Cytochrome P-450 CYP2D6; Female; Flecainide; Humans; Linear Mo | 2014 |
ECGs in the ED.
Topics: Anti-Arrhythmia Agents; Bundle-Branch Block; Electrocardiography; Emergency Service, Hospital; Fleca | 2008 |
Importance of left atrial diameter and atrial fibrillatory frequency for conversion of persistent atrial fibrillation with oral flecainide.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Evaluation; Echocardio | 2002 |
Extracellular acidosis modulates drug block of Kv4.3 currents by flecainide and quinidine.
Topics: Acidosis; Animals; Anti-Arrhythmia Agents; Biological Transport, Active; Cricetinae; Cricetulus; Dis | 2003 |
QT-interval prolongation in right precordial leads: an additional electrocardiographic hallmark of Brugada syndrome.
Topics: Adult; Anti-Arrhythmia Agents; Bundle-Branch Block; Electrocardiography; Female; Flecainide; Heart C | 2003 |
Simultaneous determination of serum flecainide and its metabolites by using high performance liquid chromatography.
Topics: Adult; Anti-Arrhythmia Agents; Chromatography, High Pressure Liquid; Female; Flecainide; Humans; Mal | 2004 |
Flecainide and propafenone induced ST-segment elevation in patients with atrial fibrillation: clue to specificity of Brugada-type electrocardiographic changes.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Bundle-Branch Block; Dose-Response Relationship, Drug; | 2004 |
[Reason for worry: syncope in the morning].
Topics: Anti-Arrhythmia Agents; Circadian Rhythm; Death, Sudden, Cardiac; Diagnosis, Differential; Electroca | 2005 |
Diagnostic value of flecainide testing in unmasking SCN5A-related Brugada syndrome.
Topics: Adult; Brugada Syndrome; Electrocardiography; Female; Flecainide; Humans; Male; Middle Aged; Muscle | 2006 |
Flecainide: safety and efficacy.
Topics: Anti-Arrhythmia Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interac | 2008 |
K+ channel blocking actions of flecainide compared with those of propafenone and quinidine in adult rat ventricular myocytes.
Topics: Animals; Anti-Arrhythmia Agents; Cells, Cultured; Electrophysiology; Flecainide; Heart; Heart Ventri | 1994 |
[Atrial electrophysiological study of unexplained ischemic cerebrovascular disorders].
Topics: Adult; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cardiac Pacing, Artificial; Cere | 1995 |
Application of the Empore solid-phase extraction membrane to the isolation of drugs from blood: II. Mexiletine and flecainide.
Topics: Chemistry Techniques, Analytical; Chromatography, High Pressure Liquid; Flecainide; Humans; Membrane | 1992 |
Gas chromatography/mass spectrometry validation of high-performance liquid chromatography analysis of flecainide enantiomers in serum.
Topics: Chromatography, High Pressure Liquid; Evaluation Studies as Topic; Flecainide; Gas Chromatography-Ma | 1992 |
Correlation of symptoms with occurrence of paroxysmal supraventricular tachycardia or atrial fibrillation: a transtelephonic monitoring study. The Flecainide Supraventricular Tachycardia Study Group.
Topics: Atrial Fibrillation; Electrocardiography; Female; Flecainide; Humans; Male; Middle Aged; Predictive | 1992 |